Synaptogenix (SNPX) Competitors

Rallybio (NASDAQ:RLYB) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Does the media prefer RLYB or SNPX?

In the previous week, Rallybio had 1 more articles in the media than Synaptogenix. MarketBeat recorded 3 mentions for Rallybio and 2 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 1.44 beat Rallybio's score of 0.62 indicating that Synaptogenix is being referred to more favorably in the news media.

Company	Overall Sentiment
Rallybio	Positive
Synaptogenix	Positive

Do analysts recommend RLYB or SNPX?

Rallybio presently has a consensus price target of $10.00, indicating a potential upside of 3,125.81%. Synaptogenix has a consensus price target of $14.00, indicating a potential upside of 455.56%. Given Rallybio's higher possible upside, equities research analysts plainly believe Rallybio is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	0 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Synaptogenix	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk and volatility, RLYB or SNPX?

Rallybio has a beta of -1.35, indicating that its stock price is 235% less volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.

Is RLYB or SNPX more profitable?

Synaptogenix's return on equity of -42.14% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	N/A	-77.39%	-69.33%
Synaptogenix	N/A	-42.14%	-29.42%

Which has stronger earnings and valuation, RLYB or SNPX?

Synaptogenix has lower revenue, but higher earnings than Rallybio. Synaptogenix is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$636K	20.28	-$74.56M	-$1.35	-0.23
Synaptogenix	N/A	N/A	-$6.04M	-$10.53	-0.24

Do institutionals & insiders have more ownership in RLYB or SNPX?

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 8.7% of Rallybio shares are owned by insiders. Comparatively, 2.7% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in RLYB or SNPX?

Rallybio received 42 more outperform votes than Synaptogenix when rated by MarketBeat users. Likewise, 73.33% of users gave Rallybio an outperform vote while only 66.67% of users gave Synaptogenix an outperform vote.

Company	Underperform	Outperform
Rallybio	Outperform Votes 44 73.33%	Underperform Votes 16 26.67%
Synaptogenix	Outperform Votes 2 66.67%	Underperform Votes 1 33.33%

Summary

Rallybio beats Synaptogenix on 9 of the 16 factors compared between the two stocks.